Clinical Trials Browser

Phase 1 × Lymphoma × olaparib × Clear all

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03575078 2019-09-25

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Phase 1 Withdrawn

Lymphoma